Notice: Undefined index: HTTP_ACCEPT_LANGUAGE in /home/stockstowatch/public_html/wp-content/mu-plugins/GrULw0.php on line 4

Notice: Undefined index: HTTP_ACCEPT_LANGUAGE in /home/stockstowatch/public_html/wp-content/mu-plugins/GrULw0.php on line 4
What 5 Analyst Ratings Have To Say About IVERIC bio – Stocks to Watch
  • Wed. Apr 24th, 2024

What 5 Analyst Ratings Have To Say About IVERIC bio

ByBenzinga Insights

Aug 2, 2022
What 5 Analyst Ratings Have To Say About IVERIC bio

[ad_1]

Within the last quarter, IVERIC bio ISEE has observed the following analyst ratings:









Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 3 1 1 0 0
Last 30D 1 0 0 0 0
1M Ago 0 1 0 0 0
2M Ago 2 0 0 0 0
3M Ago 0 0 1 0 0

These 5 analysts have an average price target of $22.0 versus the current price of IVERIC bio at $10.51, implying upside.

Below is a summary of how these 5 analysts rated IVERIC bio over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts are on the stock

This current average has decreased by 12.0% from the previous average price target of $25.00.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

[ad_2]

Image and article originally from www.benzinga.com. Read the original article here.